Key Takeaways
- Beyfortus, also known as nirsevimab, is a long-acting monoclonal antibody that helps prevent severe respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
- It is not a conventional vaccine and is currently not listed as a routine vaccination under Singapore’s National Childhood Immunisation Schedule (NCIS).
- Eligibility depends on factors such as age, RSV season, medical risk, and current clinical recommendations.
- Parents should speak with a healthcare professional about whether Beyfortus is appropriate and how it fits alongside routine children NCIS vaccinations.
Respiratory syncytial virus (RSV) is a common respiratory virus that can cause serious lower respiratory tract disease in some infants.
Parents may therefore wonder whether Beyfortus, the brand name for nirsevimab, is included in Singapore’s National Childhood Immunisation Schedule. The distinction matters because Beyfortus works differently from routine vaccines. Understanding this can help parents plan children NCIS vaccinations appropriately.
Is Beyfortus Included in the NCIS?
No. Beyfortus is not included as a routine vaccine under Singapore’s NCIS. It is a monoclonal antibody designed to provide passive protection against RSV rather than a conventional vaccine that stimulates the body to develop its own immune response.
Singapore’s NCIS covers routine childhood immunisations against diseases such as tuberculosis, hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, pneumococcal disease, measles, mumps, rubella, and varicella.
This means Beyfortus is not a replacement for routine children NCIS vaccinations. Instead, it may be considered as an additional preventive option for eligible infants when recommended by a healthcare professional.
What Is Beyfortus?
Beyfortus contains nirsevimab, a long-acting monoclonal antibody. Rather than teaching the immune system to make its own antibodies through vaccination, it provides a ready-made antibody that targets RSV.
This is why Beyfortus is sometimes described as RSV immunisation rather than an RSV vaccine. Its purpose is to provide passive protection during a period when an infant may be particularly vulnerable to severe infection.
In Singapore, Beyfortus has received regulatory approval for preventing RSV lower respiratory tract disease in newborns and infants during their first RSV season. An additional indication covers certain children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
How Does Nirsevimab Differ From a Vaccine?
A vaccine stimulates the immune system to produce its own immune response. Nirsevimab works differently because the protective antibody is administered directly.
| Feature | Beyfortus (Nirsevimab) | Routine Childhood Vaccine |
| Type | Monoclonal antibody | Vaccine |
| Protection | Passive immunity | Active immunity |
| Main target | RSV | Depends on the vaccine |
| Purpose | Reduce risk of severe RSV disease | Prevent specific infections |
| NCIS status | Not a routine NCIS vaccine | Included when listed in the NCIS |
Understanding this difference helps parents distinguish Beyfortus from children NCIS vaccinations and understand why it follows a different recommendation pathway.
Why Might an Infant Need RSV Protection?
RSV can cause bronchiolitis or pneumonia. The risk of severe disease is higher among very young infants and children with certain underlying conditions.
Healthcare professionals may consider an infant’s age, gestational age at birth, medical conditions, and other risk factors when assessing whether RSV antibody protection may be beneficial.
Not every infant needs nirsevimab, and recommendations may change over time with local guidance, RSV activity, and availability.
Is Beyfortus Given Instead of Routine Childhood Vaccines?
No. Beyfortus does not replace routine immunisations. Parents should continue following the recommended NCIS schedule unless their child’s healthcare provider advises otherwise. This keeps NCIS vaccinations for children on track.
Routine NCIS vaccinations for kids remain important because they protect against several serious infectious diseases. Nirsevimab addresses a different infection and uses a different method of protection.
If your baby is due for routine NCIS immunisations and you are also considering RSV protection, your healthcare provider can advise how the different preventive measures can be incorporated into your child’s care plan.
Who May Be Eligible for Beyfortus?
Eligibility depends on the approved indication and the child’s circumstances. Newborns and infants entering their first RSV season may be considered, while certain vulnerable children may be eligible during a second RSV season.
Additional consideration may apply to some premature infants and children with chronic lung, heart, immune, or other conditions associated with severe RSV disease.
Parents should not assume that a child qualifies solely because of age. A review of children NCIS vaccinations can also help identify which routine immunisations are due.
Does Beyfortus Provide Complete Protection?
No preventive treatment provides an absolute guarantee against infection or illness. Nirsevimab is intended to reduce the risk of severe RSV lower respiratory tract disease, rather than eliminate every possible RSV infection.
Parents should still practise sensible infection-control measures, including hand hygiene, avoiding close contact with people who are unwell, and keeping babies away from smoke.
Parents should seek medical attention if a young infant appears significantly unwell or has difficulty breathing.
How Does Beyfortus Fit Into a Child’s Vaccination Plan?
A child’s NCIS immunisation plan should continue to follow the NCIS schedule. Routine children NCIS vaccinations protect against multiple diseases and are an important part of preventive healthcare throughout childhood.
Beyfortus may be considered separately when RSV protection is indicated. It should therefore be viewed as an additional preventive measure rather than another routine NCIS vaccine for children.
Parents can track routine immunisations through the Child Health Booklet and discuss additional protection with their healthcare provider.
Frequently Asked Questions
Is Beyfortus a vaccine?
No. Beyfortus is a monoclonal antibody containing nirsevimab. It provides passive immunity against RSV rather than stimulating the immune system in the same way as a conventional vaccine.
Is Beyfortus part of the NCIS?
It is currently not included as a routine vaccine under Singapore’s NCIS. Its use follows separate clinical and regulatory recommendations.
Does my child still need children NCIS vaccinations?
Yes. Beyfortus does not replace the routine immunisations included in Singapore’s NCIS. These vaccinations protect against different vaccine-preventable diseases.
Conclusion
Beyfortus is an important option for RSV prevention, but it should not be confused with a routine childhood vaccine. Nirsevimab is a long-acting monoclonal antibody that provides passive protection against severe RSV disease in eligible infants and certain vulnerable young children.
At present, Beyfortus is not listed as a routine vaccination under Singapore’s NCIS. It therefore does not replace children NCIS vaccinations, which remain an essential part of protecting children against serious vaccine-preventable diseases.
If you are considering Beyfortus for your baby, speak with a qualified healthcare professional about your child’s age, health history, RSV risk, and current recommendations. They can explain whether nirsevimab is appropriate and how it can fit alongside your child’s routine immunisation schedule.
References
Ccintl.sg. Beyfortus – The RSV Antibody for Newborns. https://ccintl.sg/beyfortus/
Publichealth.jhu.edu. The Latest in RSV Protection for Kids: An Antibody Treatment Called Beyfortus. https://publichealth.jhu.edu/2023/beyfortus-provides-rsv-protection-for-kids
Littlehavenfamilyclinic.sg. Beyfortus – The RSV Antibody for Newborns. https://littlehavenfamilyclinic.sg/beyfortus-the-rsv-antibody-for-newborns/